StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Cartesian Therapeutics's price to sales ratio was 140.1× on Nov 10, 2026, against 9.4× a year earlier. Over the last 5 years it ranged from 1.0× to 188.7×, with a median of 5.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 10, 2026140.1×+130.5
2025Jan 31, 20259.6×+0.7
2024Dec 31, 20248.9×+5.8
2023Dec 29, 20233.1×+1.7
2022Dec 30, 20221.4×−4.2
2021Dec 31, 20215.6×−23.1
2020Dec 31, 202028.8×−95.1
2019Dec 31, 2019123.9×+59.1
2018Jan 31, 201864.8×−4.8
2017Dec 29, 201769.6×+26.7
2016Dec 30, 201642.8×–

More Cartesian Therapeutics figures

See a number that looks wrong?